Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: A phase 1b study

Keyphrases

• Tolerability 100%
• LFA-1 100%
• Phase 1b Study 100%
• Vitrectomy 66%
• Vitreous Samples 66%
• Inflammation 33%
• Mean Concentration 33%
• High Dose 33%
• Dose Effect 33%
• Adverse Events 33%
• Clinical Trials 33%
• Pharmacokinetics 33%
• Human Subjects 33%
• Detection Threshold 33%
• Prospective Randomized Trial 33%
• Intercellular Adhesion molecule-1 (ICAM-1) 33%
• Chemical Modification 33%
• Before Surgery 33%
• Diabetic Macular Edema 33%
• Twice Daily 33%
• Posterior Segment 33%
• Detection Rate 33%
• Single Subject 33%
• Aqueous Humor 33%
• Irritation 33%
• Aqueous Samples 33%
• Intravitreal Delivery 33%
• Dislocated Intraocular Lens 33%
• Dysgeusia 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Instillation Site Irritation 16%